Li D, Darden C, Osman N, Sayeed S, Jackson L, Garbinsky D, Chauhan A. Real-world clinical and patient-reported outcomes from the longitudinal telotristat ethyl treatment registry of patients with neuroendocrine tumors. Cancer Manag Res. 2022 Oct 17;14:3009-20. doi: 10.2147/CMAR.S386419
Hagberg K, Brodtkorb T-H. Patient-reported benefits of bone-anchored transfemoral prostheses as assessed by MedTech20 ©: a general outcome measure for medical products. Prosthet Orthot Int. 2021 Aug 1;45(4):355-61.
Hofheinz RD, Bruix J, Demetri GD, Grothey A, Marian M, Bartsch J, Odom D. Effect of regorafenib in delaying definitive deterioration in health-related quality of life in patients with advanced cancer of three different tumor types. Cancer Manag Res. 2021 Jul 12;13:5523-33. doi: 10.2147/CMAR.S305939
Cuyún Carter G, Barrett AM, Kaye JA, Liepa AM, Winfree KB, John WJ. A comprehensive review of nongenetic prognostic and predictive factors influencing the heterogeneity of outcomes in advanced non-small-cell lung cancer. Cancer Manag Res. 2014 Oct 23;2014(6):437-49. doi: 10.2147/CMAR.S63603
Normann E, Olsson A, Brodtkorb T. Modular socket system versus traditionally laminated socket: a cost analysis. Prosthet Orthot Int. 2011 Mar;35(1):76-80.
Ramstrand N, Brodtkorb T. Considerations for developing an evidenced-based practice in orthotics and prosthetics. Prosthet Orthot Int. 2008;32(1):93-102.